EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Treatment Outcomes of Patients with Orbital Inflammatory Diseases: Should Steroids Still Be the First Choice?

Karim Al-Ghazzawi iD, Inga Neumann, Mareile Knetsch, Ying Chen, Benjamin Wilde, Nikolaos E Bechrakis iD, Anja Eckstein, Michael Oeverhaus

Journal of Clinical Medicine · 09.07.2024 · 13 (14) · 3998

DOI: 10.3390/jcm13143998 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 09.07.2024. Verfasst von Karim Al-Ghazzawi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Hospital Essen, 45147 Essen, Germany. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation and the University Hospital Essen, Open Access Publication Fund of the University of Duisburg-Essen., Open Access Publication Fund of the University of Duisburg-Essen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To clarify the therapy response in orbital inflammatory diseases (OID), we analyzed the treatment effects of steroid therapy, the use of disease-modifying antirheumatic drugs (DMARDS), and biologicals in our tertiary referral center cohort.

Methods

We collected the clinical and demographic data of all patients treated for non-specific orbital inflammation (NSOI) (n = 111) and IgG4-ROD (n = 13), respectively at our center from 2008 to 2020 and analyzed them with descriptive statistics. NSOI were sub-grouped according to the location into either idiopathic dacryoadenitis (DAs) (n = 78) or typical idiopathic orbital myositis (n = 32).

Results

Mean age at first clinical manifestation was significantly different between subgroups (IOI: 49.5 ± 18, IgG4-ROD: 63.2 ± 14, p = 0.0171). Among all examined OID, 63 patients (50%) achieved full remission (FR) with corticosteroids (NSOI 53%/IgG4-ROD 31%). In contrast, classic myositis showed a significantly higher response (76%). Disease-modifying drugs (DMARDS) for myositis accomplished only 33% FR (NSOI 57%) and 66% did not respond sufficiently (NSOI 43%). The biologic agent (Rituximab) was significantly more efficient: 19 of 23 patients (82%) achieved full remission and only 4 (17%) did not respond fully and needed orbital irradiation or orbital decompressive surgery.

Schlagwörter

Stichwörter der Autor:innen

IgG4-RODNSOIOIDbiologicalsdacryoadenitisinflammationlacrimal glandmyositissteroids

Autor:innen und Institutionen

  • Department of Ophthalmology, University Hospital Essen, 45147 Essen, Germany.
  • Department of Nephrology, University Hospital Essen, 45147 Essen, Germany.

ORCID-Profile: Karim Al-Ghazzawi, Nikolaos E Bechrakis

Förderung

  • German Research Foundation and the University Hospital Essen
  • Open Access Publication Fund of the University of Duisburg-Essen.
  • Open Access Publication Fund of the University of Duisburg-Essen

Zitieren

APA

Al-Ghazzawi, K., Neumann, I., Knetsch, M., Chen, Y., Wilde, B., Bechrakis, N. E., Eckstein, A., & Oeverhaus, M. (2024). Treatment Outcomes of Patients with Orbital Inflammatory Diseases: Should Steroids Still Be the First Choice?. Journal of Clinical Medicine, 13(14), 3998. https://doi.org/10.3390/jcm13143998

Vancouver

Al-Ghazzawi K, Neumann I, Knetsch M, Chen Y, Wilde B, Bechrakis NE, et al. Treatment Outcomes of Patients with Orbital Inflammatory Diseases: Should Steroids Still Be the First Choice?. Journal of Clinical Medicine. 2024;13(14):3998. doi:10.3390/jcm13143998

BibTeX
@article{AlGhazzawi2024,
  author = {Al-Ghazzawi, Karim and Neumann, Inga and Knetsch, Mareile and Chen, Ying and Wilde, Benjamin and Bechrakis, Nikolaos E and Eckstein, Anja and Oeverhaus, Michael},
  title = {Treatment Outcomes of Patients with Orbital Inflammatory Diseases: Should Steroids Still Be the First Choice?},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {14},
  pages = {3998},
  doi = {10.3390/jcm13143998}
}
Kostenlos starten →